Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 700, pseudogene (RN7SL700P) is classified as a processed pseudogene, representing a non-functional, partial, or truncated copy of the functional 7SL RNA gene sequence[4][7]. While the canonical 7SL RNA plays a key role as a structural RNA in the signal recognition particle (SRP) ribonucleoprotein complex involved in co-translational protein targeting to the endoplasmic reticulum[1][3], the 7SL pseudogenes—including RN7SL700P—do not produce functional RNA products and lack biological roles in active cellular processes. Instead, these pseudogenes are considered remnants of ancient retrotransposition events in the human genome, often lacking regulatory regions or critical gene segments necessary for transcription and function[7]. Additional explanation and context: - Most 7SL "pseudogenes" are genomic relics derived from the retrotransposition of 7SL RNA sequences and do not produce functional RNAs[7]. Only a small number of true, transcriptionally active 7SL RNA genes exist in the human genome; the rest, like RN7SL700P, are considered inactive byproducts. - “RNA, 7SL, cytoplasmic” refers to a family of RNAs associated with the signal recognition particle (SRP), crucial for directing newly synthesized proteins to the endoplasmic reticulum. The pseudogene form RN7SL700P is not expressed or functional in this pathway[7]. - There are no known drugs, biomarkers, disease associations, or safety concerns related to this specific pseudogene since it does not encode a functional product. - The target entry is considered “incorrect” in a pharmacological or therapeutic context as it is neither a receptor, enzyme, nor any actionable therapeutic biomolecule. Summary of main issues: - RN7SL700P is a pseudogene and not a druggable target, nor involved in any confirmed biological or disease process. - Its record may be included in databases for genome annotation and evolutionary studies, but it is irrelevant as a therapeutic target[4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 700, pseudogene (RN7SL700P).